NCT02586402View on ClinicalTrials.gov

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Chronic Renal FailureAnemiaDialysis
Interventions
DRUG

pegol-Sihematide

DRUG

Epoetin Alfa

Trial Locations (1)

200003

RECRUITING

Changzheng Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY